Krystal Biotech, Inc. KRYS Change in AR
Change in AR at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s change in ar.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s change in AR?
- Krystal Biotech, Inc. (KRYS) reported change in AR of -$58K in Q1 2026.
- How has Krystal Biotech, Inc.'s change in AR changed year-over-year?
- Krystal Biotech, Inc.'s change in AR increased by 96.1% year-over-year, from -$1.49M to -$58K.
- What does change in AR mean?
- The change in cash owed by customers for credit sales.
- How do you interpret change in AR?
- An increase in receivables relative to revenue may signal slower collection cycles or credit risk, while a decrease indicates efficient cash conversion.
- How does change in AR compare across companies?
- A key metric for assessing the quality of earnings and the efficiency of the accounts receivable collection process.